SCHEMBL1611004

SCHEMBL1611004

CCCC/C=[C]\c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.38
LMNA P02545 1/20 0.36
DNM1 Q05193 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
TSHR P16473 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2D6 P10635 1/20 0.35
PCSK9 Q8NBP7 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 2/20 0.33
PTGS2 P35354 1/20 0.33
APP P05067 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960967 1.00 LTA4H (0.38) LTA4HLMNADNM1TDP1CYP1A2
SCHEMBL7382992 0.94 LTA4H (0.39) LTA4HLMNADNM1TDP1CYP3A4
SCHEMBL1610492 0.94 LTA4H (0.39) LTA4HLMNADNM1TDP1CYP3A4
SCHEMBL17558059 0.92 DNM1 (0.41) LTA4HLMNADNM1TDP1TSHR
SCHEMBL1610523 0.92 DNM1 (0.41) LTA4HLMNADNM1TDP1TSHR
SCHEMBL3939370 0.92 DNM1 (0.41) LTA4HLMNADNM1TDP1TSHR
SCHEMBL26092597 0.92 DNM1 (0.41) LTA4HLMNADNM1TDP1TSHR
SCHEMBL8735182 0.92 DNM1 (0.41) LTA4HLMNADNM1TDP1TSHR
SCHEMBL1610832 0.87 APP (0.36) LTA4HLMNACYP1A2CYP3A4CYP2C9
SCHEMBL6158433 0.87 APP (0.36) LTA4HLMNACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5276008-A Herbicides and plant growth regulators BAYER AKTIENGESELLSCHAFT (DE) 1994-01-04 US claimed
EP-0502307-A2 Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones BAYER AG (DE) 1992-09-09 EP claimed
WO-2023224055-A1 PHARMACEUTICAL COMPOSITION FOR USE IN THERAPEUTIC OR PROPHYLACTIC METHOD FOR KIDNEY INJURY, COMBINED MEDICINE CONTAINING SAID PHARMACEUTICAL COMPOSITION, AND CCBL1 INHIBITOR 学校法人藤田学園 2023-11-23 WO disclosed
US-11045402-B2 Hair cosmetic composition KAO CORPORATION (JP) 2021-06-29 US disclosed
US-10959925-B2 Hair cosmetic composition KAO CORPORATION (JP) 2021-03-30 US disclosed
EP-3228302-B1 HAIR DEFORMATION TREATMENT AGENT KAO CORP (JP) 2020-09-02 EP disclosed
CN-106999382-B Hair deforming agent 花王株式会社 2020-07-10 CN disclosed
US-10662259-B2 Glycogen-based water solubility enhancers AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2020-05-26 US disclosed
CN-105143274-B Glycogen-based water-soluble enhancer 方济各安吉利克化学联合股份有限公司 2020-05-05 CN disclosed
EP-2981557-B1 GLYCOGEN-BASED WATER SOLUBILITY ENHANCERS ACRAF (IT) 2020-02-05 EP disclosed
US-20190290564-A1 HAIR COSMETIC COMPOSITION KAO CORPORATION (JP) 2019-09-26 US disclosed
WO-1992012159-A1 BRIDGED CYCLIC KETAL DERIVATIVES GLAXO GROUP LIMITED (GB) 1992-07-23 WO disclosed
EP-0204285-B1 IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-01-15 EP disclosed
US-5047557-A Complexes having optically active ligands, a process for their preparation and their use CIBA-GEIGY CORPORATION (US) 1991-09-10 US disclosed
EP-0387196-A1 Complexes with optically active ligands, process for their preparation and their use CIBA-GEIGY AG (CH) 1990-09-12 EP disclosed
US-4914196-A CHIRAL REACTANTS FOR ALDEHYDES, KETONES, N-SUBSTITUTED IMINES CIBA-GEIGY CORPORATION (US) 1990-04-03 US disclosed
US-4826965-A Metal complexes containing optically active sugar ligands, a process for their preparation and their use as chiral reactants for synthesis of alcohols and amines CIBA-GEIGY CORPORATION (US) 1989-05-02 US disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed
US-4725601-A Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-02-16 US disclosed
EP-0204285-A1 Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662259-B2 Glycogen-based water solubility enhancers GYS2, GYS1, PYGL LTA4H 2128/4885LMNA 110/4885DNM1 4415/4885
US-11045402-B2 Hair cosmetic composition CUTA, GRHPR, POLR1C LTA4H 2150/4885LMNA 1954/4885DNM1 2784/4885
US-10959925-B2 Hair cosmetic composition CUTA, POLR1C, GRHPR LTA4H 3271/4885LMNA 1387/4885DNM1 3558/4885
US-20190290564-A1 HAIR COSMETIC COMPOSITION GRHPR, POLR1C, TYR LTA4H 2755/4885LMNA 1849/4885DNM1 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.